title: Influence of H pylori on plasma ghrelin in patients without atrophic gastritis.
abstract: OBJECTIVE
  To determine the association between H pylori infection and serum ghrelin levels in patients without atrophic gastritis.
  
  
  METHODS
  Fifty consecutive patients (24 males and 26 females) with either H pylori-positive gastritis (n = 34) or H pylori-negative gastritis (n = 16) with normal gastric acid secretion determined by 24-h pHmetry and without atrophic gastritis in histopathology were enrolled in this study. Thirty-four H pylori-infected patients were treated with triple therapy consisting of a daily regimen of 30 mg lansoprazole bid, 1 g amoxicillin bid and 500 mg clarithromycin bid for 14 d, followed by an additional 4 wk of 30 mg lansoprazol treatment. H pylori infection was eradicated in 23 of 34 (67.6%) patients. H pylori-positive patients were given eradication therapy. Gastric acidity was determined via intragastric pH catheters. Serum ghrelin was measured by radioimmunoassay (RIA).
  
  
  RESULTS
  There was no significant difference in plasma ghrelin levels between H pylori-positive and H pylori-negative groups (81.10 +/- 162.66 ng/L vs 76.51 +/- 122.94 ng/L). In addition, there was no significant difference in plasma ghrelin levels and gastric acidity levels measured before and 3 mo after the eradication therapy.
  
  
  CONCLUSIONS
  H pylori infection does not influence ghrelin secretion in patients with chronic gastritis without atrophic gastritis.
authors.affiliation: Gazi University, Department of Gastroenterology, Ankara, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Cindoruk
authors.forename: Ilhan
authors.initials: I
authors.lastname: Yetkin
authors.forename: Serpil Muge
authors.initials: SM
authors.lastname: Deger
authors.forename: Tarkan
authors.initials: T
authors.lastname: Karakan
authors.forename: Erdal
authors.initials: E
authors.lastname: Kan
authors.forename: Selahattin
authors.initials: S
authors.lastname: Unal
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005756:Gastritis / Q000097:blood* / Q000382:microbiology; D054439:Ghrelin; D016481:Helicobacter Infections / Q000097:blood* / Q000188:drug therapy; D016480:Helicobacter pylori / Q000472:pathogenicity / Q000502:physiology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D036361:Peptide Hormones / Q000097:blood*; D014421:Turkey
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D054439:Ghrelin; D036361:Peptide Hormones; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin